Pyxis Oncology Inc (PYXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has a cash flow conversion efficiency ratio of -0.193x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.28 Million) by net assets ($68.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Pyxis Oncology Inc to measure how much of total assets are equity-financed.
Pyxis Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pyxis Oncology Inc (PYXS) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Pyxis Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pyxis Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sao Ta Foods JSC
VN:FMC
|
0.089x |
|
Xtra-Gold Resources Corp
TO:XTG
|
0.121x |
|
Arla Plast AB
ST:ARPL
|
0.093x |
|
Bien Sparebank ASA
OL:BIEN
|
0.207x |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
-0.014x |
|
Peace Acquisition Corp Ordinary Shares
NASDAQ:PECE
|
3.620x |
|
Erciyas Celik Boru Sanayi A.S.
IS:ERCB
|
0.593x |
|
Sao Mai Group Corp
VN:ASM
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Pyxis Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Pyxis Oncology Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Pyxis Oncology Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $120.75 Million | $-57.67 Million | -0.478x | +15.09% |
| 2023-12-31 | $125.70 Million | $-70.71 Million | -0.563x | -1.26% |
| 2022-12-31 | $160.82 Million | $-89.33 Million | -0.555x | -310.90% |
| 2021-12-31 | $261.31 Million | $-35.33 Million | -0.135x | -120.97% |
| 2020-12-31 | $-15.64 Million | $-10.08 Million | 0.645x | -17.26% |
| 2019-12-31 | $-2.87 Million | $-2.24 Million | 0.779x | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more